Steve Cartt
Direktor/Vorstandsmitglied bei Neurelis, Inc.
Aktive Positionen von Steve Cartt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.01.2020 | - |
Karriereverlauf von Steve Cartt
Ehemalige bekannte Positionen von Steve Cartt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Direktor/Vorstandsmitglied | - | 01.01.2023 |
ASTERIAS BIOTHERAPEUTICS INC | Direktor/Vorstandsmitglied | 29.02.2016 | 08.03.2019 |
Vorstandsvorsitzender | 29.02.2016 | 25.06.2017 | |
Präsident | 29.02.2016 | 25.06.2017 | |
LINEAGE CELL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 04.11.2014 | 28.02.2016 |
MALLINCKRODT PLC | Corporate Officer/Principal | 01.08.2014 | 01.10.2014 |
QUESTCOR PHARMACEUTICALS INC | Geschäftsführer | 28.02.2012 | 01.08.2014 |
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Vertrieb & Marketing | 01.03.2000 | 01.08.2002 |
ALZA CORPORATION | Corporate Officer/Principal | 01.07.1985 | - |
Ausbildung von Steve Cartt
Santa Clara University | Masters Business Admin |
University of California, Davis | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Irland | 2 |
Schweiz | 2 |
Operativ
Director/Board Member | 4 |
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 9 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
MALLINCKRODT PLC | Health Technology |
Private Unternehmen | 6 |
---|---|
Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
ALZA Corp.
ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Asterias Biotherapeutics, Inc.
Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Health Technology |
TXP Pharma AG (Switzerland)
TXP Pharma AG (Switzerland) Pharmaceuticals: MajorHealth Technology Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million. | Health Technology |
- Börse
- Insiders
- Steve Cartt
- Erfahrung